Accessibility Menu
Delcath Systems logo

Delcath Systems(NASDAQ) DCTH

Current Price$12.83
Market Cap$434.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year+28%
1 Year+12%
1 Month+8%
Delcath Systems last closing stock price
MetricPriceDate
Last closeUSD 12.592026-07-20
Delcath Systems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.18%USD 12.872026-07-13
1 month+7.7%USD 11.692026-06-18
3 month+18.11%USD 10.662026-04-21
Year to date+24.65%USD 10.102025-12-31
1 year+11.91%USD 11.252025-07-18
3 year+156.94%USD 4.902023-07-21
5 year+27.95%USD 9.842021-07-21
Since inception-100%USD 7,460,000,000.002014-04-09

Delcath Systems Financials at a Glance

Market Cap

$434.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$90.44M

Net Income (TTM)

$561.00K

EPS (TTM)

$0.01

P/E Ratio

2098.33

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$12.83

Volume

2,805

Open

$12.55

Previous Close

$12.59

Daily Range

$12.55 - $12.96

52-Week Range

$8.12 - $13.74

Estimated Earnings Date

Aug 5, 2026

DCTH News

Foolcom-Featured.png

Delcath (DCTH) Q2 Revenue Jumps 210%

Motley Fool Markets TeamAug 6, 2025

DCTH: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Delcath Systems

Delcath helps doctors treat cancers that start in or spread to the liver. It makes systems that deliver high-dose chemotherapy directly to the organ. These products limit how much medicine reaches the rest of the body during treatment.

Fighting Cancer in the Liver

  • HEPZATO KIT: Combined drug and device system approved in the United States for treating eye cancer that has spread to the liver.
  • CHEMOSAT: Stand-alone medical device used in Europe to deliver and filter chemotherapy for various liver cancer types.

New Steps and Partnerships

  • Launched the first commercial use of the HEPZATO KIT in the United States in January 2024.
  • Cleared regulatory paths in December 2024 and April 2025 for new clinical trials in colorectal and breast cancers.
  • Entered a National Drug Rebate Agreement with CMS in October 2025 to expand patient access through government programs.

Precise and Repeatable Care

The system treats the entire liver to target both visible tumors and microscopic cancer cells. Medical teams can repeat the procedure several times to help manage the disease as it progresses.

Recent Financial Performance

  • Revenue rose to $20.7 million in Q4 2025, up 37.3% from the previous year.
  • Gross profit reached $17.7 million in Q4 2025, up 36.6% year-over-year.
  • Net income was -$1.9 million in Q4 2025, a result that narrowed by 44.2% from Q4 2024.
  • Free cash flow turned positive at $7.7 million in Q4 2025, up 723.3% from the prior year.

Bottom Line

Delcath has moved from a research focus to a commercial business with active sales in two major markets. Its technology provides a unique way to treat advanced liver cancer without exposing the whole body to high-dose drugs.

AI Generated • May 7, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

156

CEO

Gerard J. Michel, MBA

Website

www.delcath.com

Headquarters

Queensbury, NY 10019, US

DCTH Financials

Key Financial Metrics (TTM)

Gross Margin

85.97%

Operating Margin

-1.79%

Net Income Margin

0.62%

Return on Equity

0.51%

Return on Capital

0.59%

Return on Assets

0.45%

Earnings Yield

0.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$434.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

34.52M

Volume

2.81K

Avg. Volume

476.27K

Financials (TTM)

Gross Profit

$77.75M

Operating Income

-$1.62M

EBITDA

$1.67M

Operating Cash Flow

$21.17M

Capital Expenditure

-$1.98M

Free Cash Flow

$19.19M

Cash & ST Invst.

$89.30M

Total Debt

$907.00K

Delcath Systems Performance Analysis

Delcath Systems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,719,000-23.5%
20232023-12-31USD 2,065,000-24.1%
20242024-12-31USD 37,205,0001701.7%
20252025-12-31USD 85,231,000129.1%
Delcath Systems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.1%
Q32025-09-30-14.9%
Q42025-12-310.8%
Q12026-03-3120.6%
Delcath Systems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.1214.7%
20232023-12-31USD -2.94-28.7%
20242024-12-31USD -0.93-68.5%
20252025-12-31USD 0.07N/A
Delcath Systems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30148.1%
Q32025-09-30-68.7%
Q42025-12-31-328.6%
Q12026-03-3137.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$24.99M

+26.3%

Gross Profit

$21.26M

+25.5%

Gross Margin

85.05%

N/A

Market Cap

$434.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.79M

N/A

Employees

156

N/A

Net Income

-$1.07M

-200.1%

EBITDA

-$806.00K

-160.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$89.30M

+51.6%

Total Debt

$907.00K

-10.7%

Accounts Receivable

$15.26M

+6.1%

Inventory

$9.81M

+37.5%

Long Term Debt

$815.00K

-10.0%

Short Term Debt

$92.00K

-16.4%

Return on Assets

0.45%

N/A

Return on Invested Capital

-1.42%

N/A

Free Cash Flow

$287.00K

-86.1%

Operating Cash Flow

$857.00K

-61.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NPCENeuroPace, Inc.
$15.67-0.49%
SMLRSemler Scientific, Inc.
$20.33-4.87%
MASS908 Devices Inc.
$7.30+3.78%
BWAYBrainsWay Ltd.
$16.02-2.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.09+0.01%
MARAMara Holdings
$12.39+0.06%
UTZUtz Brands
$14.09+0.89%
HLHecla Mining
$15.32+0.07%

Questions About DCTH

What is the current price of Delcath Systems?

Delcath Systems is trading at $12.83 per share.

What is the 52-week range for Delcath Systems?

Over the past 52 weeks, Delcath Systems has traded between $8.12 and $13.74.

How much debt does Delcath Systems have?

As of the most recent reporting period, Delcath Systems reported total debt of $907.00K.

How much cash does Delcath Systems have on hand?

Delcath Systems reported $41.31M in cash and cash equivalents in its most recent financial results.

What is Delcath Systems’s dividend yield?

Delcath Systems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services